This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lucore, C. L. Articles by Sobel, B. E. Search for Related Content PubMed PubMed Citation Articles by Lucore, C. L. Articles by Sobel, B. E.

Circulation, Vol 77, 906-914, Copyright © 1988 by American Heart Association

ARTICLES

Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation

CL Lucore, ET Fry, DA Nachowiak and BE Sobel
Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110.

Biochemical modification of tissue-type plasminogen activator (t-PA) designed to alter pharmacokinetics and pharmacodynamics offers promise for development of pharmaceuticals particularly suitable for treatment of specific disorders and for induction of coronary thrombolysis by intramuscular as well as intravenous administration. Accordingly, to identify biochemical determinants of clearance of t-PA from the circulation, we injected rabbits intravenously with three different preparations of t-PA synthesized from the same human gene and expressed in Chinese hamster ovary cells cultured under disparate conditions. Influences of glycosylation on clearance were defined by experiments with enzymatically treated t-PA in which clearance was assessed with concomitant administration of selected neoglycoproteins that compete with t-PA for specific glycoprotein receptors. The role of an intact active catalytic site, as reflected by differences in clearance with and without prior treatment of t-PA with the protease inhibitor PPACK, was defined also. Results indicate that clearance is altered by inhibition of the active site and that the nature and extent of glycosylation--not evident simply by analysis of peptide structure-- influence clearance as well. These findings suggest that mannose/N- acetylglucosamine-specific glycoprotein receptors expressed on hepatic reticuloendothelial cells participate in clearance of t-PA from the circulation but that galactose-specific glycoprotein receptors probably do not. The observations may explain differences in clearance seen with different preparations of t-PA that have been seen in clinical pilot studies and may identify biochemical determinants of clearance amenable to modification for development of agents with potentially desirable, specific biological properties.

This article has been cited by other articles:

				C. Renard, O. Chappey, M. P. Wautier, M. Nagashima, J. Morser, J. M. Scherrmann, and J. L. Wautier The Human and Rat Recombinant Receptors for Advanced Glycation End Products Have a High Degree of Homology but Different Pharmacokinetic Properties in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1458 - 1466. [Abstract] [Full Text]